Companies · Pharmaceuticals

Olfax, Llc

ASHEVILLE · Pharmaceuticals

Diligence memoA one-page analyst read on Olfax, Llc — recommendation, valuation, rhythm, risks.
$110K
Total raised · real
1
Rounds
Latest step-up
Top 100%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu May 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Olfax, Llc looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.21× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era.
Quiet
  • Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
  • Slightly overdue versus sector cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Olfax, Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
2.1 yr record
Peak capital year was 2024 with $110K across 1 filings.
Market position
ahead of 1% of Pharmaceuticals peers
Capital scale is ahead of 1% of Pharmaceuticals peers; modeled value is above 1% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2024: $110K across 1 filings.
  • Largest single filing was $110K on 2024-05-30.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Olfax, Llc is one of 1610 Pharmaceuticals companies tracked from ASHEVILLE. By capital raised it ranks in the long tail (ahead of 1% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2024-05-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250K$500K$750K$1.0MPre-Seed · 2024-05-30 Raised $110K (real) Modeled valuation $524K (est)$110K$524KPre-Seed2024

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$110K · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$524K
Base estimate est.
$62K
Conservative case
$1.8M
Upside case
$611K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
2.1 yr
Elapsed time used
2.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
2.1 yr
On record since
2024
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$110K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.3× of median
This company$110K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$524K
Sector median$76.1M

Raised more than 1% of sector peers (real $). Modeled value above 1% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #37 of 38.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$10K$100K$1.0M$10.0MCapital raised (log)Eleison Pharmaceuticals Inc · Pre-Seed Raised $980K · modeled $15.9M (est)Telomir Pharmaceuticals, Inc. · Pre-Seed Raised $1.0M · modeled $9.7M (est)Drusolv Therapeutics, Inc. · Pre-Seed Raised $500K · modeled $8.5M (est)TF Tech Ventures, Inc. · Pre-Seed Raised $625K · modeled $8.3M (est)Thyron Pharmaceuticals, Inc. · Pre-Seed Raised $500K · modeled $8.2M (est)Gelesis Holdings, Inc. · Pre-Seed Raised $576K · modeled $7.9M (est)MEDPhlow, LLC · Pre-Seed Raised $1.0M · modeled $6.5M (est)Centaur Bio Inc. · Pre-Seed Raised $1.5M · modeled $5.5M (est)7 Hills Pharma Inc. · Pre-Seed Raised $1.0M · modeled $4.9M (est)Artin Bioscience Inc. · Pre-Seed Raised $483K · modeled $4.8M (est)Precision Genetics, Inc. · Pre-Seed Raised $1.0M · modeled $4.8M (est)Zena Therapeutics Inc. · Pre-Seed Raised $500K · modeled $3.8M (est)Olfax, Llc (this company) Raised $110K · modeled $524K (est)Olfax, Llc
CompanyStageRaised · realValue · estvs peer med.
Eleison Pharmaceuticals IncPre-Seed$980K$15.9M6.25×
Telomir Pharmaceuticals, Inc.Pre-Seed$1.0M$9.7M3.81×
Drusolv Therapeutics, Inc.Pre-Seed$500K$8.5M3.33×
TF Tech Ventures, Inc.Pre-Seed$625K$8.3M3.25×
Thyron Pharmaceuticals, Inc.Pre-Seed$500K$8.2M3.23×
Gelesis Holdings, Inc.Pre-Seed$576K$7.9M3.10×
MEDPhlow, LLCPre-Seed$1.0M$6.5M2.57×
Centaur Bio Inc.Pre-Seed$1.5M$5.5M2.15×
7 Hills Pharma Inc.Pre-Seed$1.0M$4.9M1.94×
Artin Bioscience Inc.Pre-Seed$483K$4.8M1.88×
Precision Genetics, Inc.Pre-Seed$1.0M$4.8M1.87×
Zena Therapeutics Inc.Pre-Seed$500K$3.8M1.50×
Olfax, Llc this companyPre-Seed$110K$524K0.21×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$110K2024-05-30$611K$524K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$110K2024-05-30
    • First recorded raise — entered as Pre-Seed.
    • 3 investors on this round.
Intelligence
Modeled next raise
$176K
Modeled next size est.range $114K$282K
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Jason T Cook1 other2024-05
Jonathan Beckwith2024-05
Wesley J Cook2024-05
Registry & provenance

Olfax, Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2026135
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Presa Solutions IncPharmaceuticalsPre-Seed$110K$1.1Msame sector · same stage
Viking Scientific, Inc.PharmaceuticalsPre-Seed$114K$4.7Msame sector · same stage
PSG of Sarasota, LLCPharmaceuticalsPre-Seed$114K$5.4Msame sector · same stage
Return Health Inc.PharmaceuticalsPre-Seed$115K$3.1Msame sector · same stage
HealthScripts of America - Portland, LLCPharmaceuticalsPre-Seed$105K$5.0Msame sector · same stage
Uppi, LlcPharmaceuticalsPre-Seed$105K$5.0Msame sector · same stage
ALVP Holdings, LLCPharmaceuticalsPre-Seed$117K$5.5Msame sector · same stage
Solaeromed Inc.PharmaceuticalsPre-Seed$101K$4.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Oligomerix, Inc.PharmaceuticalsSeed$37.8M85%
EPALEX CorpPharmaceuticalsSeries B$5.0M82%
TamRx, LLCPharmaceuticalsPre-Seed$33.1M82%
Vaccinex, Inc.PharmaceuticalsSeries A$935K81%
Havix Group, IncPharmaceuticalsSeed$22.8M81%
Infacare Pharmaceutical CorpPharmaceuticalsSeries A$108.4M81%
L.E.A.F. Pharmaceuticals LLCPharmaceuticalsSeries C$1.4B81%
MBX Biosciences, Inc.PharmaceuticalsSeries C$723.4M81%
Frequently asked
How much funding has Olfax, Llc raised?
Olfax, Llc has raised approximately $110K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Olfax, Llc's estimated valuation?
Provath's modeled valuation for Olfax, Llc is approximately $524K (modeled range $62K–$1.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Olfax, Llc at?
Olfax, Llc's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu May 30.
What does Olfax, Llc do and where is it based?
Olfax, Llc operates in the Pharmaceuticals sector, based in ASHEVILLE.
Explore related

See where Olfax, Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Olfax, Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.